Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Verastem Jumped Higher Today

By Brian Orelli, PhD - Aug 9, 2018 at 3:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Hint: It has nothing to do with yesterday's earnings release.

What happened

Shares of Verastem (VSTM 0.00%) are up 10.7% at 2:32 p.m. EDT after the company released second-quarter earnings after the closing bell yesterday. The company doesn't have any drugs on the market, so it's not the financial results that are encouraging investors to hit the buy button today.

For the record, Verastem lost $18.4 million, or $0.30 per share, in the second quarter. Importantly, the company burned through about $20 million in cash during the quarter but has $168.7 million in the bank, thanks to raising approximately $105 million selling shares through three different vehicles: a public offering, a registered offering to funds managed by Consonance Capital, and an at-the-market equity offering program.

Micrograph of purple stained cancer cells

Image source: Getty Images.

So what

As there was no obvious news, it appears investors are just piling on today ahead of the Food and Drug Administration (FDA) decision for duvelisib, which is under review for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

The FDA has set a target action date of Oct. 5, 2018, but that's just a goal that the agency is trying to meet based on the Prescription Drug User Fee Act (PDUFA). The agency -- especially the oncology division -- has approved many drugs weeks or even months ahead of the PDUFA date. Verastem got an accelerated approval for duvelisib, implying the FDA sees an unmet need for patients with late-stage CLL/SLL, so the agency isn't likely to drag its feet on an approval.

Now what

While many investors like to buy in ahead of binary events like FDA decisions, not every FDA approval results in a pop in the stock price. In fact, considering duvelisib's positive phase 3 results, it seems very likely that the FDA will approve the drug -- meaning the upside could be limited or even result in a sell-the-news event.

Verastem shares are up 180% this year, so investors should be careful buying ahead of an approval, especially since the additional shares sold via the offerings will result in investors owning a smaller piece of the overall pie.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Verastem, Inc. Stock Quote
Verastem, Inc.
$1.25 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.